Voyager Therapeutics, Inc. (VYGR)

$6.76

-0.32

(-4.52%)▲

Market is closed - opens 7 PM, 10 Oct 2024

Performance

  • $6.57
    $7.08
    $6.76
    downward going graph

    2.81%

    Downside

    Day's Volatility :7.2%

    Upside

    4.52%

    downward going graph
  • $5.71
    $11.72
    $6.76
    downward going graph

    15.53%

    Downside

    52 Weeks Volatility :51.28%

    Upside

    42.32%

    downward going graph

Returns

PeriodVoyager Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-11.28%
4.7%
0.0%
6 Months
-22.11%
5.9%
0.0%
1 Year
-5.98%
16.3%
0.0%
3 Years
47.5%
19.6%
-20.8%

Highlights

Market Capitalization
386.1M
Book Value
$6.16
Earnings Per Share (EPS)
0.27
PE Ratio
26.22
PEG Ratio
0.0
Wall Street Target Price
17.63
Profit Margin
6.28%
Operating Margin TTM
-50.8%
Return On Assets TTM
-1.11%
Return On Equity TTM
3.38%
Revenue TTM
143.8M
Revenue Per Share TTM
2.84
Quarterly Revenue Growth YOY
509.5%
Gross Profit TTM
-19.9M
EBITDA
-1.8M
Diluted Eps TTM
0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.4
EPS Estimate Next Year
-1.81
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Voyager Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 160.8%

Current $6.76
Target $17.63

Company Financials

FY18Y/Y Change
Revenue
7.6M
↓ 24.82%
Net Income
-88.3M
↑ 24.88%
Net Profit Margin
-1.2K%
↓ 461.23%
FY19Y/Y Change
Revenue
104.4M
↑ 1270.14%
Net Income
-40.8M
↓ 53.75%
Net Profit Margin
-39.11%
↑ 1119.68%
FY20Y/Y Change
Revenue
171.1M
↑ 63.93%
Net Income
36.7M
↓ 189.98%
Net Profit Margin
21.47%
↑ 60.58%
FY21Y/Y Change
Revenue
37.4M
↓ 78.14%
Net Income
-66.0M
↓ 279.72%
Net Profit Margin
-176.49%
↓ 197.96%
FY22Y/Y Change
Revenue
40.9M
↑ 9.33%
Net Income
-46.4M
↓ 29.72%
Net Profit Margin
-113.45%
↑ 63.04%
FY23Y/Y Change
Revenue
250.0M
↑ 511.16%
Net Income
132.3M
↓ 385.14%
Net Profit Margin
52.93%
↑ 166.38%
Q1 FY23Q/Q Change
Revenue
150.5M
↓ 466.25%
Net Income
124.0M
↓ 625.03%
Net Profit Margin
82.43%
↑ 24.93%
Q2 FY23Q/Q Change
Revenue
4.9M
↓ 96.77%
Net Income
-22.2M
↓ 117.9%
Net Profit Margin
-457.61%
↓ 540.04%
Q3 FY23Q/Q Change
Revenue
4.6M
↓ 4.92%
Net Income
-25.9M
↑ 16.63%
Net Profit Margin
-561.36%
↓ 103.75%
Q4 FY23Q/Q Change
Revenue
90.1M
↑ 1851.91%
Net Income
56.4M
↓ 317.73%
Net Profit Margin
62.62%
↑ 623.98%
Q1 FY24Q/Q Change
Revenue
19.5M
↓ 78.33%
Net Income
-11.3M
↓ 120.09%
Net Profit Margin
-58.05%
↓ 120.67%
Q2 FY24Q/Q Change
Revenue
29.6M
↑ 51.56%
Net Income
-10.1M
↓ 10.49%
Net Profit Margin
-34.29%
↑ 23.76%
FY18Y/Y Change
Total Assets
177.0M
↓ 4.04%
Total Liabilities
130.6M
↑ 158.96%
FY19Y/Y Change
Total Assets
354.8M
↑ 100.4%
Total Liabilities
255.2M
↑ 95.47%
FY20Y/Y Change
Total Assets
261.6M
↓ 26.26%
Total Liabilities
107.3M
↓ 57.98%
FY21Y/Y Change
Total Assets
193.9M
↓ 25.89%
Total Liabilities
98.8M
↓ 7.89%
FY22Y/Y Change
Total Assets
159.4M
↓ 17.8%
Total Liabilities
100.3M
↑ 1.55%
FY23Y/Y Change
Total Assets
351.3M
↑ 120.44%
Total Liabilities
115.0M
↑ 14.58%
Q1 FY23Q/Q Change
Total Assets
336.3M
↑ 111.03%
Total Liabilities
119.3M
↑ 18.93%
Q2 FY23Q/Q Change
Total Assets
315.5M
↓ 6.17%
Total Liabilities
116.5M
↓ 2.37%
Q3 FY23Q/Q Change
Total Assets
294.7M
↓ 6.62%
Total Liabilities
118.4M
↑ 1.65%
Q4 FY23Q/Q Change
Total Assets
351.3M
↑ 19.22%
Total Liabilities
115.0M
↓ 2.93%
Q1 FY24Q/Q Change
Total Assets
469.6M
↑ 33.68%
Total Liabilities
128.7M
↑ 11.96%
Q2 FY24Q/Q Change
Total Assets
436.2M
↓ 7.11%
Total Liabilities
100.8M
↓ 21.68%
FY18Y/Y Change
Operating Cash Flow
-15.9M
↓ 74.1%
Investing Cash Flow
26.5M
↓ 819.02%
Financing Cash Flow
4.7M
↓ 92.07%
FY19Y/Y Change
Operating Cash Flow
48.7M
↓ 406.33%
Investing Cash Flow
-90.5M
↓ 441.85%
Financing Cash Flow
81.0M
↑ 1605.5%
FY20Y/Y Change
Operating Cash Flow
-96.7M
↓ 298.73%
Investing Cash Flow
113.0M
↓ 224.89%
Financing Cash Flow
3.2M
↓ 96.09%
FY21Y/Y Change
Operating Cash Flow
-53.5M
↓ 44.66%
Investing Cash Flow
65.9M
↓ 41.67%
Financing Cash Flow
612.0K
↓ 80.65%
FY22Y/Y Change
Operating Cash Flow
-12.5M
↓ 76.63%
Investing Cash Flow
-7.3M
↓ 111.14%
Financing Cash Flow
1.1M
↑ 81.37%
Q1 FY23Q/Q Change
Operating Cash Flow
123.6M
↓ 1109.19%
Investing Cash Flow
14.5M
↑ 3.01%
Financing Cash Flow
31.3M
↑ 11242.75%
Q2 FY23Q/Q Change
Operating Cash Flow
-835.0K
↓ 100.68%
Investing Cash Flow
-24.7M
↓ 270.2%
Financing Cash Flow
1.5M
↓ 95.06%

Technicals Summary

Sell

Neutral

Buy

Voyager Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
14.38%
-22.11%
-5.98%
47.5%
-54.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.19%
6.5%
20.85%
84.03%
245.65%
Novo Nordisk A/s
Novo Nordisk A/s
-11.15%
-6.13%
27.31%
138.21%
354.53%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.12%
73.95%
61.12%
32.59%
252.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.58%
13.46%
29.21%
155.56%
172.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
26.22
26.22
0.0
-1.4
0.03
-0.01
NA
6.16
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.59
26.59
1.37
45.03
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.73
39.73
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
Buy
$386.1M
-54.16%
26.22
6.28%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.8B
245.65%
26.59
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$522.1B
354.53%
39.73
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.2B
252.19%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.5B
172.0%
32.84
-4.74%

Insights on Voyager Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 19.51M → 29.57M (in $), with an average increase of 34.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -11.33M → -10.14M (in $), with an average increase of 11.7% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 67.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 5.5%

Institutional Holdings

  • BlackRock Inc

    9.74%

  • Armistice Capital, LLC

    9.54%

  • EcoR1 Capital, LLC

    7.18%

  • Vanguard Group Inc

    5.57%

  • Farallon Capital Management, L.L.C.

    4.20%

  • State Street Corp

    3.28%

Company Information

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.

Organization
Voyager Therapeutics, Inc.
Employees
162
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs